RefleXion Medical Raises $100 Million Series C to Commercialize Revolutionary Cancer Treatment


RefleXion Medical, a medical technology company developing the first and only biology-guided radiotherapy system for targeted cancer treatment, announced today it has raised more than $100 million in a Series C round of funding led by The Rise Fund, the global impact investment fund managed by TPG Growth. Also participating were T. Rowe Price Associates, Inc., China-focused healthcare investment firm GT Healthcare Capital Partners, and all existing investors including Sofinnova Partners, KCK Group, Venrock as well as corporate investors Pfizer Venture Investments and Johnson & Johnson Innovation – JJDC Inc. “Radiation therapy has a long history of effectively treating cancer patients.

Go to Source

Read more, visit source